Department of Surgery, University of Illinois College of Medicine at Peoria, Peoria, IL, USA.
Department of Radiation Oncology, H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL, USA.
Surgery. 2018 May;163(5):1020-1027. doi: 10.1016/j.surg.2017.11.020. Epub 2018 Jan 8.
Radioembolization induces liver hypertrophy, although the extent and rate of hypertrophy are unknown. Our goal was to examine the kinetics of contralateral liver hypertrophy after transarterial radioembolization.
A retrospective study (2010-2014) of treatment-naïve patients with primary/secondary liver malignancies undergoing right lobe radioembolization was performed. Computed tomography volumetry was performed before and 1, 3, and 6 months after radioembolization. Outcomes of interest were left lobe (standardized future liver remnant) degree of hypertrophy, kinetic growth rate, and ability to reach goal standardized future liver remnant ≥40%. Medians were compared with the Kruskall-Wallis test. Time to event analysis was used to estimate time to reach goal standardized future liver remnant.
In the study, 25 patients were included. At 1, 3, and 6 months, median degree of hypertrophy was 4%, 8%, and 12% (P < .001), degree of hypertrophy relative to baseline future liver remnants was 11%, 17%, and 31% (P = .015), and kinetic growth rate was 0.8%, 0.5%, and 0.4%/week (P = .002). In patients with baseline standardized future liver remnant <40% (N= 16), median time to reach standardized future liver remnant ≥40% was 7.3 months, with 75% accomplishing standardized future liver remnant ≥40% at 8.2 months.
Radioembolization induces hypertrophy of the contralateral lobe to a similar extent as existing methods, although at a lower rate. The role of radioembolization as a dual therapy (neoadjuvant and hypetrophy-inducing) for selected patients needs to be studied. (Surgery 2017;160:XXX-XXX.).
肝动脉栓塞术(TACE)可诱导肝组织发生代偿性增生,但目前对于增生的程度和速度还知之甚少。本研究旨在探讨 TACE 后对侧肝脏增生的动力学变化。
对 2010 年至 2014 年期间行 TACE 治疗的初治原发性或转移性肝癌患者进行回顾性研究。所有患者在 TACE 治疗前、治疗后 1、3、6 个月时行 CT 容积扫描。感兴趣的结局包括左叶(标准剩余肝体积)的增生程度、增长速率以及达到标准剩余肝体积≥40%的时间。使用 Kruskal-Wallis 检验对中位数进行比较。使用生存分析估计达到目标标准剩余肝体积的时间。
本研究共纳入 25 例患者。治疗后 1、3、6 个月,左叶的增生程度分别为 4%、8%和 12%(P<.001),与基线时剩余肝体积相比,分别为 11%、17%和 31%(P=.015),增长速率分别为 0.8%、0.5%和 0.4%/周(P=.002)。在基线时标准剩余肝体积<40%的患者(n=16)中,达到标准剩余肝体积≥40%的中位时间为 7.3 个月,82%的患者在 8.2 个月时达到标准剩余肝体积≥40%。
TACE 诱导对侧肝脏增生的程度与现有的方法相似,但增生速度较慢。需要进一步研究 TACE 作为一种双重治疗(新辅助治疗和诱导增生)方法在特定患者中的作用。(《外科》杂志 2017;160:XXX-XXX.)。